Modulated Imaging, an Irvine, CA-based developer of imaging systems for both scientific and medical application, secured an initial $500k seed financing.
The round was led by the Cove Fund with participation from Hamamatsu Photonics KK through its wholly-owned subsidiary, Photonics Management Corporation.
The company intends to use the funds to continue to develop its medical technology.
Led by David Cuccia, PhD, CEO & CTO, Modulated Imaging develops patented Spatial Frequency Domain Imaging tissue-imaging devices that allow medical, research and aesthetics professionals to prevent, diagnose and cure underlying skin conditions. The company’s first medical device, the Ox-Imager CS, which is pending FDA clearance, is targeted to rapid and wide-area perfusion studies in a variety of applications, from vascular labs to chronic wound management.
Modulated Imaging has been self-funded through sales of their Reflect RS scientific instrument, and approximately $8m in research grants from the National Institutes of Health and Department of Defense.